Is patience still a virtue when managing ROP? The most common cause of pediatric blindness in the United States is retinopathy of prematurity (ROP), a condition characterized by abnormal angiogenesis following incomplete retinal vascularization in premature infants. Surgical management of ROP involves cryotherapy or laser therapy to avascular retina – however prior to the ETROP study, standard of care involved waiting to intervene until risk of retinal detachment or macular folds reached ≥ 50% (“threshold” ROP). ETROP was a randomized control trial to determine whether early ablation for “prethreshold” ROP (risk ≥ 15%) would improve visual acuity and structural outcomes compared to conventional management.
Key Points:
- At 9 months of age, early peripheral retinal ablation significantly reduced unfavorable visual (from 19.5% to 14.5%, p=.01) and structural outcomes (from 15.6% to 9.1%, P < 0.001).
- Further analysis revealed a new clinical algorithm for early prethreshold ROP treatment: Type 1 ROP (Zone I, any stage ROP with plus disease; Zone I, stage 3 ROP without plus disease; or Zone II, stage 2 or 3 with plus disease) should be managed with immediate intervention, while Type 2 ROP (zone I, stage I or 2 ROP without plus disease or zone II, stage 3 ROP without plus disease) should be closely monitored.
- Patients were followed until 6 years of age and the structural benefits of early treatment persisted for eyes with high-risk prethreshold ROP; however, visual acuity benefits were only present for eyes with type 1 ROP.
ET-ROP was a landmark study that established the current treatment guidelines for ROP, demonstrating the structural and visual benefits of early intervention for eyes with type 1 ROP. However even with early treatment, 65.4% of eyes still developed visual acuity worse than 20/40, indicating the fundamental limitations in ROP management.
|
|